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Pauci-Immune Glomerulonephritis in Individuals With
Disease Associated With Levamisole-Adulterated Cocaine
A Series of 4 Cases
Adam Q. Carlson, MD, Delphine S. Tuot, MD, Kuang-Yu Jen, MD, Brad Butcher, MD,
Jonathan Graf, MD, Ramin Sam, MD, and John B. Imboden, MD
Abstract: Exposure to levamisole-adulterated cocaine can induce
a distinct clinical syndrome characterized by retiform purpura
and/or agranulocytosis accompanied by an unusual constellation of
serologic abnormalities including antiphospholipid antibodies, lupus
anticoagulants, and very high titers of antineutrophil cytoplasmic
antibodies. Two recent case reports suggest that levamisole-
adulterated cocaine may also lead to renal disease in the form of
pauci-immune glomerulonephritis. To explore this possibility, we
reviewed cases of pauci-immune glomerulonephritis between 2010
and 2012 at an inner city safety net hospital where the prevalence
of levamisole in the cocaine supply is known to be high. We
identified 3 female patients and 1 male patient who had biopsy-
proven pauci-immune glomerulonephritis, used cocaine, and had
serologic abnormalities characteristic of levamisole-induced
autoimmunity. Each also had some other form of clinical disease
known to be associated with levamisole, either neutropenia or
cutaneous manifestations. One patient had diffuse alveolar hemor-
rhage. Three of the 4 patients were treated with short courses of
prednisone and cyclophosphamide, 2 of whom experienced stable
long-term improvement in their renal function despite ongoing
cocaine use. The remaining 2 patients developed end-stage renal
disease and became dialysis-dependent. This report supports
emerging concern of more wide spread organ toxicity associated
with the use of levamisole-adulterated cocaine.
(Medicine 2014;93: 290–297)
Abbreviations: AAV = ANCA-associated vasculitis, ANCA =
antineutrophil cytoplasmic antibody, APLA = antiphospholipid
antibody, ANA = antinuclear antibody, cANCA = cytoplasmic
antineutrophil cytoplasmic antibody, CIMDL = cocaine-induced
midline destructive lesion, ELISA = enzyme-linked immuno-
sorbent assay, GN = glomerulonephritis, GPA = granulomato-
sis with polyangiitis, HNE = human neutrophil elastase, IIF =
indirect immunofluorescence, LAC = lupus anticoagulant,
MPA = microscopic polyangiitis, MPO = myeloperoxidase,
NET = neutrophil extracellular trap, pANCA = perinuclear
antineutrophil cytoplasmic antibody, PR3 = proteinase 3, PTU
= propylthiouracil.
INTRODUCTION
Now licensed exclusively as an antihelminthic for use inveterinary medicine, levamisole was once used as a
putative immunomodulatory agent for the treatment of a
variety of autoimmune conditions and malignancies. Toxicity
eventually led to its withdrawal for human use in 1999. The
most worrisome toxicities seen in adults were neutropenia
and agranulocytosis, which occurred in 2.5%–13% of
patients and resolved promptly with drug discontinua-
tion.22,25,34 Small numbers of pediatric patients treated with
prolonged courses of levamisole for refractory nephrotic
syndrome developed a distinctive rash characterized by
retiform purpura distributed on the face (nose, cheeks, and
ear lobes) and proximal extremities. Biopsies of these
purpuric lesions demonstrated thrombosis of superficial and
deep dermal vessels with varying degrees of leukocytoclastic
vasculitis. Children with these rashes also had circulating
antineutrophil cytoplasmic antibodies (ANCAs) and antiphos-
pholipid antibodies (APLAs). Upon discontinuation of
levamisole, the purpura resolved within 2–3 weeks, and the
autoantibodies disappeared over 2–14 months.20,28
In 2005, levamisole appeared as an adulterant in illicit
cocaine entering the United States, presumably added by
suppliers in an effort to increase cocaine volumes and
enhance the perceived quality of the drug.5,16 The prevalence
of this adulterant remained low through 2007 (detected in
<10% of cocaine bricks seized by the United States Drug
Enforcement Agency) but then rose sharply. By 2010,
approximately 80% of all seized stocks of cocaine contained
levamisole,4 indicating that exposure to levamisole had
become almost ubiquitous among regular cocaine users.
Indeed, 2 recent studies from inner-city hospitals identified
levamisole in 63%–88% of urine samples that tested positive
for cocaine.3,18 Levamisole toxicity has re-emerged as a
medical problem with multiple reports linking the use of
levamisole-adulterated cocaine to neutropenia, life-threaten-
ing agranulocytosis, and retiform purpura of the face and
extremities.26,36,37,42 As reported in pediatric cases, adults
with retiform purpura linked to levamisole-adulterated
cocaine have an unusual combination of serologic
abnormalities. First, they possess high titer ANCAs which
stain in a perinuclear pattern (pANCA) due to autoantibodies
against multiple components of neutrophil granules, includ-
ing myeloperoxidase (MPO), proteinase 3 (PR3), human
neutrophil elastase (HNE), lactoferrin, and cathepsin G. They
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also test positive for a lupus anticoagulant (LAC) and have
APLAs, usually in the form of IgM antibodies to cardioli-
pin.12,37
A conspicuous feature of clinical disease associated with
levamisole-adulterated cocaine has been the paucity of organ
involvement aside from the skin and granulocytes. Two recent
case reports, however, raised the possibility of an association
between the use of levamisole-adulterated cocaine and glomeru-
lonephritis (GN).14,19 In the current study, we extend those
observations and report 4 cases of biopsy-proven pauci-immune
GN seen at a single institution over a 2-year period. All patients
were active users of cocaine, had serologic abnormalities
characteristic of levamisole-induced autoimmunity, and had at
least 1 other clinical manifestation linked to use of levamisole
(retiform purpura, digital infarcts, or neutropenia). These
observations suggest that use of levamisole-adulterated cocaine
can trigger a pauci-immune GN similar to that seen with the
primary ANCA vasculitides, granulomatosis with polyangiitis
(GPA) and microscopic polyangiitis (MPA).
METHODS
We reviewed the medical records of all cases of pauci-
immune GN seen at San Francisco General Hospital from
2010 through 2012. The study was approved by the San
Francisco General Hospital institutional review board. For
inclusion in this series, patients had to have the following:
1) pauci-immune GN on renal biopsy, 2) cocaine exposure
confirmed either by patient history or by urine toxicology
studies, and 3) serologic abnormalities characteristic of levami-
sole-induced autoimmunity. We defined the latter as a positive
test for ANCA in a perinuclear pattern (pANCA) by indirect
immunofluorescence (IIF) together with at least 1 of the
following: simultaneous presence of antibodies to MPO and
PR3 by enzyme-linked immunosorbent assay (ELISA), a LAC
detected by dilute Russell viper venom time, or presence of
IgM antibodies to cardiolipin. Because nearly 90% of cocaine
in San Francisco is adulterated with levamisole, we accepted
cocaine use as a proxy for levamisole exposure.18 Renal
biopsies were reviewed by a renal pathologist (KJ) to confirm
the presence of pauci-immune GN.
RESULTS
We identified 3 female patients and 1 male patient who
had biopsy-proven pauci-immune GN, used cocaine, and had
serologic abnormalities characteristic of levamisole-induced
autoimmunity. All patients reported smoking cocaine, and all
tested positive for cocaine on urine toxicology screens,
except for 1 who was anuric. Each had some form of clinical
disease known to be associated with levamisole, either
neutropenia or cutaneous disease manifesting as retiform
purpura or digital infarcts (Table 1). All patients had
elevated levels of serum creatinine, and the 3 patients who
were not anuric on presentation had proteinuria and an active
urinary sediment, defined as the presence of dysmorphic red
blood cells or the presence of red blood cell casts (Table 2).
All 4 patients had pANCAs in titers ³1:320 as measured by
IIF. Two patients had antibodies to both MPO and PR3,
whereas the others had antibodies to MPO alone. Three
patients either tested positive for a LAC or had a circulating
IgM antibody to cardiolipin (Table 3).
Kidney biopsies from each patient in this series demon-
strated changes consistent with pauci-immune GN. Three
TABLE 1. Clinical Characteristics of Patients Presenting With Pauci-Immune Glomerulonephritis Associated With Levamisole-
Adulterated Cocaine Exposure
Patient Age (yr) Sex Arthritis/Arthralgia Skin Disease Pulmonary Hemorrhage Neutropenia (k/μL)
Case 1 60 M Yes Retiform purpura/digital infarcts No No (2.88)
Case 2 49 F No Retiform purpura Yes No (9.31)
Case 3 63 F Yes None No Yes (0.52)
Case 4 43 F No Hemorrhagic bullae/digital infarcts No No (4.18)
TABLE 2. Renal Manifestations and Outcomes of Patients Presenting With Pauci-Immune Glomerulonephritis Associated With
Levamisole-Adulterated Cocaine Exposure
Patient
Baseline
Creatinine
(mg/dL)
Presenting
Creatinine
(mg/dL) Urine Sediment
Urine
Pr:Cr* Biopsy Result Therapy
Follow-Up
Creatinine
(mg/dL)
Case 1 0.60 1.60 Dysmorphic RBCs 2.0 Necrotizing pauci-immune GN Brief prednisone, IV
cytoxan
1.37
Case 2 0.50 7.31 Dysmorphic RBCs 4.9 Focal segmental and global
sclerosing glomerulopathy
with cellular crescents
Prednisone, plasma-
pheresis, brief
IV cytoxan
Dialysis
Case 3 0.76 3.25 Hematuria (urine
microscopy not
done)
0.7 Necrotizing pauci-immune GN Prednisone, brief
oral cytoxan
1.13
Case 4 1.60 14.2 Anuric Anuric Necrotizing pauci-immune GN None Dialysis
*Urine protein-to-creatinine ratio.
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biopsies (Cases 1, 3, and 4) exhibited evidence of recent/
ongoing activity as supported by numerous cellular crescents
and necrotizing lesions, while the other biopsy (Case 2)
showed more remote signs of glomerular injury with presence
of fibrous and fibrocellular crescents. The latter biopsy also
revealed a higher percentage of global glomerulosclerosis and
a greater degree of interstitial fibrosis and tubular atrophy,
findings associated with chronic stages of GN. Otherwise, the
nonsclerotic glomeruli in all biopsies were essentially unre-
markable with no significant endocapillary proliferation,
mesangial widening, or mesangial hypercellularity. The
biopsies showed no evidence of thrombotic microangiopathy
or malignant hypertension, which can be seen in association
with cocaine use.13 The larger vessels within the renal
parenchyma showed no evidence of frank vasculitis. Immuno-
fluorescence for IgG, IgM, IgA, C3 and C1q was negative in
all cases, supporting the diagnosis of pauci-immune GN.
Ultrastructural analysis by electron microscopy confirmed the
absence of electron dense immune-type deposits.
Three of the 4 patients were treated with short courses of
prednisone and cyclophosphamide. Two of the treated patients
had stable long-term improvement in their renal function
despite ongoing cocaine use. The remaining 2 patients devel-
oped end-stage renal disease and became dialysis-dependent.
Case 1
A 60-year-old man with a history of chronic cocaine
use was admitted with a 2-week illness characterized by
polyarthralgia and the development of retiform purpura on
TABLE 3. Immunologic and Coagulation Profiles of Patients Presenting With Pauci-Immune Glomerulonephritis Associated
With Levamisole-Adulterated Cocaine Exposure
Patient ANCA IF
MPO
(AU/mL)1
PR3
(AU/mL)*
Cardiolipin
IgM (MPL)†
LAC
(RVVT)
ANA IF
(titer)
C3
(mg/dL)‡
C4
(mg/dL)§
Case 1 1:10240 Perinuclear Positive (114) Positive (187) Positive (52) Positive 1:320 speckled 82 18
Case 2 1:5120 Perinuclear Positive (137) Negative (4) Negative Positive <1:40 110 24
Case 3 1:320 Perinuclear Positive (29) Negative (18) Indeterminate (13) Negative <1:40 101 27
Case 4 1:5120 Perinuclear Positive (69) Positive (36) Positive (25) Negative <1:40 47 20
*Negative <19AU/mL, Indeterminate 20–25AU/mL, Positive >25AU/mL.
†Negative 0–12 MPL, Indeterminate 13–19 MPL, Weak Positive 20–80 MPL, Strong Positive >81 MPL.
‡Normal 86–184mg/dL.
§Normal 20–59mg/dL.
FIGURE 1. Kidney biopsy histologic findings. A) Glomerulus from Case 1 with a large cellular crescent (methenamine silver-periodic
acid-Schiff; 400x). B) Glomerulus from Case 1 showing fibrin (arrow) of a necrotizing lesion (trichrome; 400x). C) Medium power
view of biopsy from Case 4 demonstrating a range of cellular to fibrocellular crescents. Features of mild interstitial fibrosis, tubular
atrophy, and interstitial inflammation are also noted (periodic acid-Schiff; 100x). D) Glomerulus from Case 4 showing a small
cellular crescent with associated fibrin of a necrotizing lesion (arrow) (hematoxylin & eosin; 400x).
292 | www.md-journal.com ã 2014 Lippincott Williams & Wilkins
Carlson et al Medicine • Volume 93, Number 17, October 2014
the upper extremities and overlying the zygomatic arches of
the face. Serum creatinine was 1.60mg/dL, increased from a
baseline of 0.60mg/dL measured 4 months previously.
Urinalysis revealed proteinuria and hematuria with dysmor-
phic red blood cells. A urine toxicology screen was positive
for cocaine. Serologic studies were notable for a high titer
pANCA and the presence of antibodies to MPO and PR3. He
tested positive for a LAC and had IgM and IgG antibodies to
cardiolipin. Biopsy of a purpuric lesion revealed congestion
and thrombosis of the superficial and mid-dermal vessels
without evidence of leukocytoclastic vasculitis. A kidney
biopsy showed pauci-immune GN with focal necrotizing
lesions and crescent formation (Figure 1A and 1B).
Three daily intravenous doses of 500mg methylpred-
nisolone were administered, followed by oral prednisone
60mg daily. During the 10-day hospitalization, the skin
lesions improved and the serum creatinine, which had
peaked at 2.16mg/dL, improved to 1.64mg/dL. After
discharge, the patient continued using cocaine and discon-
tinued all prescribed medications. Two weeks later, he was
readmitted with recurrent retiform purpura and a creatinine
of 2.51mg/dL. Urine microscopy revealed a persistently
active urine sediment. Oral prednisone was restarted, and he
received a single 750mg dose of intravenous cyclophospha-
mide. Over the next 2 weeks his skin lesions resolved, and
creatinine improved to 1.43mg/dL. He was discharged on
prednisone alone with plans for monthly infusions of
cyclophosphamide but failed to keep any appointments. On
a visit to a different clinic 19 months after his renal biopsy,
he had a serum creatinine of 1.37mg/dL, persistent hematu-
ria and proteinuria, and a positive urine toxicology study
for cocaine.
Case 2
A 49-year-old woman with hepatitis C, chronic leg
ulcers, and a history of cocaine abuse was admitted with
painful purpuric lesions on the left leg and an associated
cellulitis. Initial laboratories on admission showed acute
kidney injury with a serum creatinine of 1.88mg/dL,
elevated from her baseline of 0.50mg/dL measured 1 year
previously. Urinalysis revealed hematuria and proteinuria,
and examination of the urine sediment demonstrated red
blood cell casts. She received parenteral antibiotics with
gradual improvement in her cellulitis. Creatinine remained
stable throughout her hospitalization, ranging from 1.72 to
1.88mg/dL. Prior to discharge, she underwent serologic
testing and a skin biopsy of the purpuric lesions with plans
to follow-up as an outpatient. Skin biopsy revealed leukocy-
toclastic vasculitis and rare fibrin thrombi of the superficial
and deep dermal vessels. Serologic studies were notable for
the presence of antibodies to MPO and IgM antibodies to
cardiolipin. She had no antibodies to PR3. She did not attend
any of the scheduled outpatient follow-up appointments.
Five months later, she presented with hemoptysis and
acute onset dyspnea. On presentation, she was hypoxemic
with bilateral pulmonary infiltrates on chest radiograph. She
was severely anemic with a hemoglobin of 6.7 g/dL and had
acute kidney injury with a serum creatinine of 7.31mg/dL.
Urinalysis revealed hematuria and proteinuria, and examina-
tion of the urine sediment demonstrated dysmorphic red
blood cells. A urine toxicology screen was positive for
cocaine. She was admitted to the intensive care unit with
hypoxemic respiratory failure and started urgently on hemo-
dialysis. Bronchoscopy findings were consistent with diffuse
alveolar hemorrhage.
She was transfused with several units of packed red
blood cells and received 3 daily intravenous doses of
1000mg methylprednisolone, 3 sessions of plasma exchange,
and a single intravenous dose of 500mg cyclophosphamide,
followed by oral prednisone 60mg daily. Serologic studies
were notable for a high-titer pANCA, the presence of
antibodies to MPO, and a positive test for a LAC. Renal
biopsy demonstrated presence of fibrous and fibrocellular
crescents, consistent with pauci-immune GN with evolving
chronic changes due to prior activity. Following her initial
course of therapy, the patient had no further alveolar
hemorrhage but remained dialysis-dependent.
Case 3
A 63-year-old woman with a long history of cocaine
abuse presented to her primary care provider with diffuse
pruritis and arthralgia. Serum creatinine was 3.25mg/dL, up
from her baseline of 0.76mg/dL measured 1 year previously,
which prompted a hospitalization for expedited workup. Upon
admission, she was neutropenic with an absolute neutrophil
count of 520 cells/mL, and urinalysis revealed hematuria and
proteinuria. A serologic workup was notable for a positive
pANCA at a titer of 1:320, antibodies to MPO, and a weakly
positive IgM antibody to cardiolipin. A kidney biopsy revealed
pauci-immune necrotizing and crescentic GN.
Three daily intravenous doses of 1000mg methylprednis-
olone were administered. She was then transitioned to oral
prednisone 60mg daily and oral cyclophosphamide 50mg
daily. One month after starting cyclophosphamide, she devel-
oped herpes ophthalmicus for which she was started on
intravenous acyclovir, and her cyclophosphamide was discon-
tinued. She was poorly compliant with her outpatient medi-
cations and eventually discontinued her prednisone. Serum
creatinine remained stable at approximately 1.20mg/dL over
the ensuing 24 months despite intermittent use of cocaine.
Case 4
A 43-year-old woman with hepatitis C and a history of
cocaine abuse was admitted with altered mental status.
Physical examination revealed altered mental status, a
pericardial friction rub, hemorrhagic bullae overlying her
fingers, and distal digital infracts. She was anuric and had a
serum creatinine of 14.30mg/dL. She received urgent
hemodialysis for symptomatic uremia with improvement in
her mental status. Subsequent serologic workup revealed a
pANCA with a titer of 1:5120, antibodies to both MPO and
PR3, and IgM antibodies to cardiolipin. A kidney biopsy
demonstrated pauci-immune necrotizing and crescentic GN
with presence of fibrocellular and fibrous crescents
(Figure 1C and 1D). She remained dialysis-dependent but
continued to use cocaine and died from an intracerebral
hemorrhage several months following discharge.
DISCUSSION
Levamisole-Adulterated Cocaine and Internal
Organ Manifestations
We report 4 cases of chronic cocaine users presenting
with biopsy-proven pauci-immune crescentic GN, one of
whom had concurrent diffuse alveolar hemorrhage. All
patients had clinical manifestations (skin disease or neutrope-
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nia) and serologic abnormalities characteristic of the syn-
drome associated with levamisole-adulterated cocaine. Two
other cases of biopsy-proven pauci-immune GN linked to
levamisole-adulterated cocaine have recently been published.
Gulati et al reported on a 49-year-old Hispanic man who
presented with retiform purpura, acute kidney injury, and an
active urinary sediment.14 The patient’s laboratory studies
were notable for MPO antibodies at high titers as well as a
LAC. McGrath et al reported a case involving a 53-year-old
woman who similarly presented with retiform purpura, acute
kidney injury, and an active urinary sediment.19 She tested
positive for both MPO and PR3 at high titers. Both of these
patients underwent renal biopsies, which showed pauci-
immune necrotizing crescentic GN. Taken together with the
current series, these reports support the emerging concern
that prolonged use of levamisole-adulterated cocaine can lead
to a drug-induced autoimmune disease complicated by a
clinically significant pauci-immune GN.
In contrast to neutropenia and retiform purpura, pauci-
immune GN was not observed as a complication of levami-
sole when it was used therapeutically as an immunomodula-
tory agent. There was a reported case of renal insufficiency
and GN linked to the use of levamisole for the treatment of
rheumatoid arthritis, but the renal biopsy revealed an
immune-complex-mediated proliferative GN with subepithe-
lial deposits. After withdrawal of levamisole, the patient’s
renal function improved.31 There were no purpuric rashes or
cytopenias described in this case, which antedated the
development of tests for ANCAs and APLAs. The associa-
tion of levamisole with a pauci-immune GN, therefore,
appears to represent a new clinical phenomenon.
Differentiating Levamisole-Induced Disease
From Other Forms of ANCA-Associated
Systemic Vasculitis
The primary ANCA associated vasculitides (AAVs)
include GPA, MPA, and eosinophilic microscopic polyangii-
tis. These diseases affect multiple organ systems including
the upper airways, lung parenchyma, peripheral nerves, skin,
and kidneys. The drug-induced AAVs caused by agents such
as hydralazine and propylthiouracil (PTU) manifest with
clinical features that overlap to a significant degree with the
primary forms of the disease, particularly MPA.7,10 A similar
spectrum of organ involvement appears to occur in patients
with disease associated with the use of levamisole-adulterat-
ed cocaine.19 Given variations in the treatment and prognosis
of these different vasculitides, it is important to differentiate
levamisole-induced disease from the primary and other
secondary forms of AAV.
It has been previously noted that ANCA serologies
themselves allow for differentiation of the primary and drug-
induced AAVs.10,39 Patients with disease associated with
levamisole-adulterated cocaine tend to develop high to ex-
tremely high titer ANCAs when measured by IIF, most often
in a perinuclear staining pattern. The ANCA antibodies in
these and other cases of drug-induced AAV are directed at
multiple antigenic targets within neutrophilic granules, primari-
ly MPO, HNE, cathepsin G, and lactoferrin.7,10,12,15,32,33 HNE
and cathepsin G share epitopes with PR3, and antibodies to
these can result in a falsely positive anti-PR3 immunoassay
due to cross reactivity. It is therefore possible to see a high
titer pANCA and a discordantly positive anti-PR3 antibody in
those with drug-induced AAV.30,38,39 In contrast, the primary
AAVs demonstrate modest ANCA titers on IIF due to anti-
bodies against either PR3 or MPO rather than multiple
neutrophilic antigens.38,39 Unlike the primary AAVs, many
agents linked to drug-induced AAVs, including levamisole-
adulterated cocaine, have also been shown to lead to positive
antinuclear antibodies (ANAs).7,32 Though clinical and sero-
logic similarities exist among the drug-induced AAVs, the
discriminating features of the illness associated with levami-
sole-adulterated cocaine remain its unique cutaneous manifes-
tations (retiform purpura), the frequent occurrence of
neutropenia, and the presence of APLAs and a LAC.
Differentiating the Complications of Levamisole-
Adulterated Cocaine From Those of Pure
Cocaine Use
Cocaine use, independent of the presence of adulterants,
is associated with varying rheumatic manifestations. These
include cocaine-induced midline destructive lesion (CIMDL),
organ specific and systemic vasculitides, and vascular disease
related to stimulant-induced vasospasm.11 Despite the wide-
spread use of cocaine, CIMDL and cocaine-induced vasculi-
tis remain relatively uncommon. When these clinical
manifestations do occur, they are associated with 1 of 3
serologic profiles which include: no circulating autoanti-
bodies in those with organ limited disease,6,17,21 a positive
cANCA and PR3 antibody in those with multi-systemic
disease mirroring GPA,24 and a positive pANCA and PR3
antibody in those with CIMDL.35 The unexpected serologic
discrepancy seen with CIMDL is due to the presence of
antibodies to HNE. Antibodies directed at HNE have not
been detected in patients with GPA and are rarely reported
in MPA and eosinophilic microscopic polyangiitis.38,39
Because cocaine, like levamisole, can induce loss of
tolerance to multiple targets within the neutrophilic granule, one
must rely on other features to differentiate pathology associated
with unadulterated cocaine from that of cocaine laced with
levamisole. The unique cutaneous findings associated with
levamisole are helpful if present, but otherwise one must use
discriminating laboratory features. Patients with clinical disease
associated with unadulterated cocaine have not been shown to
develop APLAs or a LAC and do not develop neutropenia.8,12
Pathophysiology
The exact mechanism by which medications such as
hydralazine, PTU, and levamisole induce ANCA-associated
syndromes remains unclear, but studies have implicated
neutrophil extracellular traps (NETS) in the pathogenesis of
these conditions.23,29 NETs are comprised of a scaffold of
chromatin DNA intermingled with histones and constituents of
cytoplasmic PMN granules, including MPO, PR3, and HNE.
These elements are released from neutrophils during a unique
form of cell death in response to various stimuli, including
intact pathogens, pathogen components, and high levels of
reactive oxygen species. Antibodies and antibody-antigen
complexes have also been shown to induce NET release,
though to a lesser degree.2 NETs may provide a source of
intact antigen capable of inducing an adaptive immune
response, leading to the production of ANCAs.29 PTU in
particular has been shown to cause production of disorganized
NETs that are resistant to normal homeostatic mechanisms of
degradation. Immunization of rats with these abnormal NETs
leads to pulmonary capillaritis and pauci-immune GN.23 It is
possible that levamisole, like PTU, acts via this mechanism to
294 | www.md-journal.com ã 2014 Lippincott Williams & Wilkins
Carlson et al Medicine • Volume 93, Number 17, October 2014
induce loss of tolerance to multiple antigens from within
neutrophil granules, resulting in clinical disease.
Genetic and environmental factors likely play a role in the
pathogenesis of disease related to levamisole exposure. Patients
carrying an HLAB27 allele are known to be at higher risk of
developing agranulocytosis when treated with levamisole.40
Demethylation of particular DNA sequences leading to altered
expression of specific genes appears to play an important role
in the pathogenesis of lupus-like syndromes induced by
procainamide and hydralazine.27,41 Whether disruption of this
type of epigenetic control also contributes to levamisole-
induced autoimmunity is not known.
Many patients on agents such as PTU and hydralazine
develop circulating ANCAs yet never develop vasculitis.15,33
This phenomenon is likely true in those exposed to levamisole
given the widespread use of cocaine, the high prevalence of
levamisole in the drug supply, and the relatively low incidence
of retiform purpura, neutropenia, and GN in chronic cocaine
users. The factors that distinguish those who develop clinical
disease from those who do not remain unclear.
One important factor seems to be the chronicity of drug
exposure. Patients with drug-induced AAVs and internal
organ involvement have typically been exposed to offending
agents for prolonged periods of time, often on the order of
years. With regard to levamisole-adulterated cocaine, it is
only in the past several years that cases of pauci-immune
GN linked to levamisole have emerged. These more recent
cases may reflect the effect of chronic exposure to levami-
sole, which has now been present in the illicit cocaine supply
since 2005. With this timeline in mind, agranulocytosis,
retiform purpura, and circulating autoantibodies may repre-
sent an earlier phase of levamisole-induced disease. With
further exposure, patients may be at increased risk of
developing renal involvement. Why patients previously
treated with prolonged courses of therapeutic levamisole
alone did not develop pauci-immune GN is unknown. It may
be that cocaine acts synergistically with levamisole to result
in a more advanced clinical phenotype. Alternatively, renal
involvement may represent a dose dependent effect of
levamisole or a variable response related to the route of drug
administration. All patients in the current series reported
smoking crack cocaine whereas all patients on therapeutic
doses of levamisole in the past took oral formulations.
Treatment
The treatment of drug-induced AAVs due to hydralazine
and PTU provides a helpful framework for strategies in those
patients with end-organ damage associated with exposure to
levamisole-adulterated cocaine. The mainstay of therapy for
drug-induced AAVs is withdrawal of the offending agent.
For patients with end-organ involvement (GN or pulmonary
hemorrhage), short courses of immunosuppressives appear to
be efficacious and result in durable remission rates provided
that patients are identified early.9,10 Patients with pulmonary
hemorrhage may be treated with plasmapheresis in addition
to immunosuppression.
In the current series, 3 of the 4 patients were treated with
short courses of prednisone and cyclophosphamide. Although
they were counseled to abstain from cocaine, all continued to
use the drug. It is noteworthy that despite these relapses and
presumed repeated exposures to levamisole, short courses of
immunosuppressive therapy were associated with improvement
and stabilization of renal function in 2 patients over the course
of 19–24 months. The other patients in the series remained
dialysis-dependent, but they initially presented with more
advanced renal disease. In contrast, the case reported by Gulati
et al was treated in the same manner as a primary AAV with a
short course of prednisone, 4 infusions of rituximab, and
maintenance with azathioprine. This treatment course was
associated with a partial remission and interval improvement
in the patient’s creatinine to a new baseline. The case
presented by McGrath et al received an unknown course of
immunosuppressives, which was also associated with a partial
remission. These cases suggest that durable responses can be
achieved with short courses of aggressive immunosuppressive
therapy even in the face of ongoing exposure to levamisole. It
is not known however whether successfully treated patients
will ultimately relapse if re-exposed to levamisole-adulterated
cocaine on a persistent basis.
Limitations
Since 88% of urine samples testing positive for cocaine
at San Francisco General Hospital also contain levamisole,18
we assumed that all patients with a history of cocaine use
were exposed to levamisole. No confirmatory studies were
performed to verify levamisole in patient samples from the
current series. We limited the scope of this series to include
only patients with biopsy-proven pauci-immune GN. It is
possible that there are other forms of GN, such as immune
complex-mediated disease, that are associated with levami-
sole use. Finally, no firm conclusions can be drawn regard-
ing the efficacy of any of the therapeutic interventions we
describe. We did not conduct a therapeutic trial, and the
natural history of pauci-immune GN associated with levami-
sole remains uncertain.
Conclusion
In conclusion, levamisole-adulterated cocaine not only
results in retiform purpura and neutropenia, but can also lead
to a pauci-immune GN, and possibly pulmonary hemorrhage,
in the setting of chronic drug exposure. There are unique
exam and laboratory findings that help differentiate the
syndrome associated with levamisole-adulterated cocaine
from the primary and drug-induced AAVs. Important
discriminating laboratory features include the presence of
APLAs and LACs in combination with high titer ANCAs
measured by IIF and positive antibodies to multiple constit-
uents of the neutrophilic granule. The mainstay of treatment
is abstinence from cocaine and, by extension, levamisole.
Though additional observations are needed, it appears that
those patients with severe end-organ involvement can be
treated with short courses of immunosuppressives without
maintenance regimens.
Cocaine is a common drug of abuse. In 2008, an
estimated 1.9 million individuals in the United States
reported cocaine use within the past month, of which
approximately 19% were current crack users.1 In light of this
widespread use and the high prevalence of levamisole in the
illicit cocaine supply in the United States, clinicians may
expect cases of drug-induced AAV with internal organ
involvement to occur with greater frequency in the future.
Given the divergent treatment strategies for primary and
drug-induced AAVs, it is important for medical providers to
maintain a high level of suspicion for disease associated with
levamisole in long-term cocaine users.
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